RESULTS OF THE CLINICAL USE OF A DROSPIRENONE-CONTAINING AGENT IN WOMEN WITH SEVERE PREMENSTRUAL SYNDROME
- Authors: PRILEPSKAYA V.N1, MEZHEVITINOVA E.A1, SASUNOVA R.A1, IVANOVA E.V1, LETUNOVSKAYA A.B1, NABIYEVA K.R1
-
Affiliations:
- Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health and Social Development of Russia
- Issue: No 2 (2012)
- Pages: 81-85
- Section: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/246730
- ID: 246730
Cite item
Open Access
Access granted
Abstract
Objective. To evaluate the therapeutic efficacy and acceptability of a low-dose combined oral contraceptive (COC) containing the spironolactone derivative drospirenone as a gestagenic component in the management of patients with premenstrual dysphoric disorder (PMDD). Subjects and methods. Thirty-nine women (mean age 29.95±1.66 years) diagnosed as having PMDD established in accordance with the generally accepted standards (DSM-IV) were followed up. Physical examination, clinical, laboratory, and instrumental studies, as well as consultations by a psychologist and a psychiatrist were performed. The low-dose COC midiana containing 30 μg ethinyl estradiol and 3 mg drospirenone was used as a 21+7 regimen in all the patients. The therapeutic efficacy of the contraceptive on the course of PMDD was evaluated using premenstrual syndrome questionnaires and diaries, as well as psychological scales for anxiety and depression and the types of psychological protection. Results. The most common psychoemotional symptoms were irritability (97.4%), nutritional behavioral impairment (89.7%), depression (84.6%), tearfulness (71.83 %), and aggressivity (66.7%); the most frequent somatic symptoms were mastodynia and mastalgia (94.9%), abdominal distention (92.3%), lower abdominal pain (82.1%), edemas (74.4%), and headache (64.1%). When used, the COC showed a high therapeutic effect in women with PMDD: following 6 months, irritability and mastodynia were observed in 24 (61.5%) and 11 (28.2%), respectively. The patients had affective improvement according to the psychological scales and questionnaires over time, by applying score rating scales. Within the first month of COC use, an inconsiderable number of women had adverse reactions: all symptoms disappeared spontaneously and did not require additional contraception or its discontinuation. The contraceptive efficiency was 100%. Conclusion. The low-dose COC containing drospirenone, 3 mg, and ethinyl estradiol, 30 μg, as a gestagenic component has a high contraceptive efficiency and does not cause significant side effects. The contraceptive favorably affects the symptoms of PMDD, by lowering their degree by an average of 40%.
Full Text
About the authors
V. N PRILEPSKAYA
Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health and Social Development of RussiaMoscow
E. A MEZHEVITINOVA
Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health and Social Development of Russia
Email: Mejevitinova@mail.ru
Moscow
R. A SASUNOVA
Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health and Social Development of RussiaMoscow
E. V IVANOVA
Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health and Social Development of RussiaMoscow
A. B LETUNOVSKAYA
Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health and Social Development of RussiaMoscow
K. R NABIYEVA
Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health and Social Development of RussiaMoscow
References
- Аганезова Н.В., Линде В.А. Клинический опыт применения комбинированного монофазного орального контрацептива с дроспиреноном при синдроме предменструального напряжения // Пробл. репрод. - 2008. -№ 1. - С. 66-72.
- Андреева Е.Н., Карпова Е.А., Пономарева Т.А. Дроспиренон - прогестаген с антиминералкортикоидными свойствами // Акуш. и гин. -2004. - № 6. -С. 51-52.
- Пасман Н.М. Дроспиренон - гестаген XXI века с антиминералокортикоидной активностью // Гинекология. - 2004. - № 2. - С. 92-96.
- Прилепская В.Н., Бостанджян Л.Л. Гормональная контрацепция: от эволюции прогестагенов к новым возможностям // Гинекология. - 2007. - № 6. -С. 20-23.
- Прилепская В.Н., Межевитинова Е.А., Назарова Н.М., Бостанджян Л.Л. Гормональная контрацепция. - М.: ГЭОТАР-Медиа, 2011.
- Сасунова Р.А., Межевитинова Е.А. Предменструальный синдром // Гинекология. - 2010. - № 6. - С. 34-38.
- Соболева Е.Л. Комбинированные оральные контрацептивы, содержащие дроспиренон или ципротерона ацетат, в терапии угревой сыпи // Журн. акуш. и жен. бол. - 2009. - № 2. - С.53-56.
- Apter D., Borsos A., Baumgärtner W. et al. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms // Eur. J. Contracept. Reprod. Hlth Care. - 2003. - Vol. 8, № 1. -P. 37-51.
- Bitzer J., Paoletti A.M. Added benefits and user satisfaction with a low-dose oral contraceptive containing drospirenone: results of three multicentre trials // Clin. Drug Invest. - 2009. - Vol. 29, № 2. - P. 73-78.
- Foidart J.M., Wuttke W., Bouw G.M. et al. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel // Eur. J. Contracept. Reprod. Hlth Care. - 2000. - Vol. 5, № 2. - P. 124-134.
- Gaspard U., Endrikat J., Desager J.P. et al. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles // Contraception. - 2004. - Vol. 69, - № 4. - P. 271-278.
- Gruber D.M., Huber J.C., Melis G.B. et al. A comparison of the cycle control, safety, and efficacy profile of a 21-day regimen of ethinylestradiol 20mug and drospirenone 3 mg with a 21-day regimen of ethinylestradiol 20 mug and desogestrel 150 mug // Treat. Endocrinol. - 2006. - Vol. 5, № 2. -P. 115-121.
- Huber J., Foidart J.M., Wuttke W. et al. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone // Eur. J. Contracept. Reprod. Hlth Care. - 2000. - Vol. 5, № 1. - P. 25-34.
- Kulier R., Helmerhorst F.M., Maitra N., Gülmezoglu A.M. Effectiveness and acceptability of progestogens in combined oral contraceptives - a systematic review// Reprod. Hlth. -2004. - Vol. 1, № 1. - P. 1.
- Motivala A., Pitt B. Drospirenone for oral contraception and hormone replacement therapy // Drugs. - 2007. - Vol. 67, № 5. - P. 647-655
- Oelkers W. Drospirenone, a progestogen with antimineralocorticoid properties: a short review // Mol. Cell. Endocrinol. - 2004. - Vol. 217, № 1-2. - P. 255-261.
- Parsey K.S., Pong A. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen // Contraception. - 2000. - Vol. 61, №2. - P. 105-111.
- Rapkin A.J. YAZ in the treatment of premenstrual dysphoric disorder // J. Reprod. Med. - 2008. - Vol. 53 (suppl. 9). -P. 729-741.
- van Vloten W.A., van Haselen C.W., van Zuuren E.J. et al. The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea // Cutis. - 2002. - Vol. 69, № 4. (suppl.). - P. 2-15.
Supplementary files
